CA-ESRI
6.10.2020 14:02:19 CEST | Business Wire | Press release
Esri , the global leader in location intelligence, today announced two major capabilities in Site Scan for ArcGIS that will enable governments and critical infrastructure organizations to meet hardware and software regulations in the US and Europe. Through an established partnership with Auterion, creator of the most widely used open-source drone autopilot operating system, security-conscious US organizations will be able to use Site Scan, Esri's unmanned aerial systems flight planning and processing solution, to plan and execute missions with the trusted and secure Freefly Astro drone, powered by Auterion. Additionally, for organizations in Europe with data sovereignty requirements, a new and fully independent instance of Site Scan for ArcGIS has been deployed to European servers, ensuring that organizational data resides within the region.
Site Scan for ArcGIS is used by organizations that require drone imagery for visual inspections, site monitoring, asset management, and situational awareness. It's an all-in-one, cloud-based drone mapping solution for managing fleets and collecting, processing, analyzing, and sharing data products. Industries using this solution include architecture, engineering, construction, natural resources, infrastructure, and government. Core capabilities in Site Scan—such as scalability, collaboration, time saving, and now enhanced security functionality—provide value to customers.
The US government has recently issued a growing number of advisory warnings and bans on the use of drones that pose security risks. These precautions have adversely impacted federal agencies and private firms that manage critical infrastructure, causing them to adopt incongruous drone data capturing and processing workflows that consist of multiple vendor solutions. Esri can now offer these agencies a single, end-to-end drone solution that integrates Freefly Astro, using US Department of Defense-approved Blue sUAS software architecture from Auterion, and is fully supported by Site Scan.
"Our expertise in providing an enterprise drone platform based on open-source software enabled us to meet the needs of the US government and governments worldwide," said Dave Sharpin, CEO, Auterion Government Solutions. "We are very excited to partner with Esri and provide [its] users with our groundbreaking technology."
By law within Europe, data from publicly funded or critical infrastructure projects cannot leave the European Union (EU). To enable a scalable drone workflow, Site Scan for ArcGIS has been deployed to a server cluster in Ireland. European customers that require their data not be transmitted outside the region can now leverage this server cluster to meet project requirements.
"The relationship we have established with Auterion is key in being able to offer high-quality, secure drone software to our US customers looking to take advantage of our advanced, secure, drone-based imagery collection and management platform," said Richard Cooke, Esri director of imagery and remote sensing. "Additionally, through the development of the EU deployment, an even wider range of customers located in Europe will be able to maintain their data and data processing locally."
The Freefly Astro and Site Scan integration will be available for customers by December 2020. The European deployment of Site Scan is available today. To learn more about the new integration of Site Scan with the Freefly Astro drone or about the EU deployment of Site Scan, contact the Esri sales team at esri.com/en-us/arcgis/products/site-scan-for-arcgis/overview#contactsales .
About Auterion
Auterion provides enterprise and government with an ecosystem of software-defined drones, payloads, and third-party applications within a single easy to use platform based on open-source standards.
With 50+ employees across offices in California and Switzerland, Auterion has raised $25M in venture-backed funding from investors such as Lakestar, Mosaic Ventures, Costanoa Ventures, and Tectonic Ventures. The company's global customer base includes GE Aviation, Quantum Systems, Freefly Systems, Avy, and the U.S. Government. Learn more at www.auterion.com .
Twitter: @auterion
LinkedIn: https://www.linkedin.com/company/auterion/
Facebook: https://www.facebook.com/auterion/
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969, Esri software is deployed in more than 350,000 organizations including 90 of the Fortune 100 companies, all 50 state governments, more than half of all counties (large and small), and 87 of the Forbes Top 100 Colleges in the U.S., as well as all 15 Executive Departments of the U.S. Government and dozens of independent agencies. With its pioneering commitment to geospatial information technology, Esri engineers the most advanced solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2020 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005312/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom